Hepatitis C and Nonalcoholic Steatohepatitis in the 21st Century: Impact on Liver Disease and Liver Transplantation

Hepatitis C infection is a leading etiology of hepatic dysfunction and major indication for liver transplantation due to the development fibrosis, cirrhosis, hepatocellular carcinoma. Nonalcoholic fatty disease (NAFLD) and, specifically, its subtype nonalcoholic steatohepatitis (NASH) rising cause disease. It predicted surpass hepatitis as transplant. The introduction direct-acting antivirals (DAAs) decreased prevalence chronic infections, but obesity epidemic metabolic syndrome have increased NASH. Weight loss dietary modifications are recommended NASH therapies, unlike C, federally approved agents lacking currently under investigation. Clinical trials face many barriers in treatment because difficulty diagnosis lack standardized accurate clinical histologic responses. Mortality morbidity heightened presence multiple comorbidities including cardiovascular disease, diabetes, renal dysfunction. A transplant may be indicated, thorough screening candidates, comprehensive assessment, essential ensuring successful outcomes pre- post-transplant. Therapeutic warranted before it becomes significant mortality worldwide.